Editas Medicine, Inc. EDIT 深 滬
已收盤 02-06 16:00:00 美东时间
1.82
+0.155
+9.31%
華盛通- 最 高1.845
- 今 開1.78
- 成交量 193.04万股
- 最 低 1.7301
- 昨 收 1.665
- 總市值 1.78亿
- 52周最高 4.5372
- 市盈率 靜 --
- 換手率 1.98%
- 52周最低 0.9101
- 委 比 -38.51%
- 總股本 9761.87万
- 歷史最高 99.95
- 量 比 1.14
- 振 幅 6.90%
- 歷史最低 0.9101
- 每 手 1
- 風險率 0.73%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Editas Medicine Q3 EPS $(0.28) Beats $(0.29) Estimate, Sales $7.543M Beat $5.020M Estimate
Editas Medicine (NASDAQ:EDIT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.29) by 5.08 percent. This is a 62.67 percent increase over losses of $(0.75) per share from
2025-11-10 20:21
Editas Medicine Announces Third Quarter 2025 Results and Business Updates
<p>Editas Medicine reported progress on its lead in vivo therapy,EDIT-401, targeting LDL-C reduction, with preclinical data showing over 90% LDL-C reduction in non-human primates. The company plans to submit an IND/CTA by mid-2026 and achieve initial human proof-of-concept data by year-end 2026. The company extended its cash runway into the third quarter of 2027. Third-quarter financials showed a net loss of $25.1 million, with collaboration reve...
2025-11-10 12:00
Editas Medicine Announces EDIT-401 Poster Presentation at the American Heart Association (AHA) Scientific Sessions 2025
Editas Medicine to Present CRISPR Gene Editing for LDL Cholesterol Reduction at AHA 2025. The presentation will discuss a transformative CRISPR-based medicine to lower LDL cholesterol. Session details: November 8, 10:45 a.m. to 11:45 a.m. CT in the Basic Science Zone at the American Heart Association Scientific Sessions in New Orleans. Anshul Gupta, Vice President of Preclinical Development, will present. The abstract is available on the AHA webs...
2025-11-03 14:00
Gene editing therapy companies rise on word of streamlined FDA approval process
Companies focused on gene editing therapies, including CRISPR Therapeutics (CRSP), Editas Medicines (EDIT), and Intellia Therapeutics (NTLA) are trading higher Friday following a report that the US FD...
2025-11-01 00:14
快讯 | 美股基因编辑概念股盘前下挫，NTLA一度暴跌超60%
基因编辑公司 $Intellia Therapeutics (NTLA.US)$ 盘前一度暴跌超60%，消息面上，该公司宣布暂停其针对转甲状腺素蛋白淀粉样伴心肌...
2025-10-27 20:17
Editas Medicine To Deliver EDIT-401 Oral Presentation At European Society Of Gene And Cell Therapy Congress, October 7–10, 2025, In Seville, Spain
Editas Medicine, Inc. (NASDAQ:EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced an oral presentation at the upcoming European Society of Gene
2025-10-06 21:05
Editas Medicine Announces EDIT-401 Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress and Participation in Upcoming Investor Conferences
Editas Medicine has announced an oral presentation at the October 7-10, 2025 European Society of Gene and Cell Therapy Congress in Seville, Spain. The presentation, titled "A transformative LDL-cholesterol–lowering in vivo CRISPR gene editing medicine," will be delivered by Linda Burkly, Ph.D., on October 9 at 5:00 p.m. CEST. Additionally, the company will participate in the H.C. Wainwright Genetic Medicines Virtual Conference on October 14 and t...
2025-10-06 13:00
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, Sept. 25, 2025 /PRNewswire/ -- America's aging demographics are creating unprecedented demand for pr...
2025-09-25 21:15
Editas Medicine Nominates EDIT-401, an LDLR-Targeted Medicine, as Lead In Vivo Development Candidate
Editas Medicine announced the nomination of EDIT-401, an experimental gene editing therapy designed to significantly reduce LDL cholesterol (LDL-C) levels. Preclinical studies showed EDIT-401 achieved ~90% mean LDL-C reduction in non-human primates, surpassing standard therapies. The company aims to advance EDIT-401 to human proof-of-concept data by end of 2026 and has a strong cash position to support operations into the second quarter of 2027. ...
2025-09-02 11:00
